Skip to content

Released Nov 13, 2020, after the close

10-Q filed Nov 13, 2020, 44 days after period end · 0001390478-20-000037

Q3 2020 · 10-Q
Revenue$0.00no prior Q3 2019 on fileno prior Q2 2020 on file
Net Income-$4.47MN/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.53N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$4,492,000—
Operating Cash Flowderived-$3,629,000N/M

What the release said

The release

Same quarter

MetricQ3 2020Q3 2019Q3 2018Q3 2017
Revenue$0.00———
Net Income-$4.47M-$4.20M-$290.00K-$4.46M
EPS Diluted-$0.53-$2.68-$26.75-$2.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR